sCD163 levels of the PDAC patients were significantly elevated than these of the healthy subjects, and sCD163 in combination with CA19-9, a pancreatic cancer marker, offered higher predictive potential than sCD163 alone [108]. This evidence concerns the gene CD163 and pancreatic neoplasm.